Genoil Inc. (GNOLF)
| Market Cap | 19.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.10M |
| Shares Out | 1.99B |
| EPS (ttm) | -0.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,280 |
| Average Volume | 7,570 |
| Open | 0.0010 |
| Previous Close | 0.0200 |
| Day's Range | 0.0010 - 0.0010 |
| 52-Week Range | n/a |
| Beta | 1,139.98 |
| RSI | 22.34 |
| Earnings Date | Aug 29, 2025 |
About Sage Therapeutics
Genoil Inc., together with its subsidiaries, engages in the development of oil and gas industry technologies in the Middle East, Russia, China, and internationally. It offers Genoil Hydroconversion Upgrader, a heavy oil upgrading technology that converts sour and heavy hydrocarbon feed stocks into lighter oil with distillates for conventional refining. The company was incorporated in 1996 and is headquartered in Newport, Rhode Island. [Read more]
Financial Performance
Financial StatementsNews
Genoil Syncrude is a National Security Interest of The United States
Genoil Project Rollout Can Prevent a Collapse in the World Economy NEW YORK CITY, NY / ACCESSWIRE / December 4, 2024 / Genoil Inc. (OTC PINK:GNOLF) announces that the Genoil Upstream Upgrading Crude P...
Genoil Completes Bankable Feasibility Study for Refinery Project in Duqm Oman
NEW YORK, NY / ACCESSWIRE / May 10, 2022 / (OTC PINK:GNOLF) Genoil announces that it has completed the bankable feasibility study for the planned refinery in Oman. The company is proceeding to finaliz...